Although these stimulators demonstrated promising therapeutic potential in preclinical and early phase clinical trials, a phase III trial of the immunomodulator Z-100 for stage IIB-IVA cervical cancer (JGOG study) showed a trend for improvement on OS, although the statistical power was less than anticipated because survival rates were unexpectedly higher for both arms ( 133 ).
1
—
—